Walvax Biotechnology Company Limited operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Walvax Biotechnology Company Limited with three other
companies in this sector in China:
Zhenxing Biopharmaceutical & Chemical Co Ltd
sales of 567.44 million Chinese Renmimbi [US$86.24 million]
of which 100%
was Pharmaceutical Sales),
Pulike Biological Engineering Inc
(583.09 million Chinese Renmimbi [US$88.62 million]
of which 93%
was Veterinary Chemicals), and
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd
(581.89 million Chinese Renmimbi [US$88.44 million]
During the year ended December of 2016, sales at
Walvax Biotechnology Company Limited were 590.16 million Chinese Renmimbi (US$89.69 million).
decrease of 41.3%
versus 2015, when the company's sales were 1.01 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 76.2% decline
in Vaccine Agency, from 578.92 million Chinese Renmimbi to 137.54 million Chinese Renmimbi.
There were also decreases in sales in
Autonomous Vaccine (down 16.7% to 222.83 million Chinese Renmimbi)
However, these declines were partially offset by the increase in sales of
Medicine Agency (up 6.3% to 122.40 million Chinese Renmimbi)
Sales of Service (up 53.4% to 36.13 million Chinese Renmimbi)
Other Operating Revenue (up 75.2% to 36.36 million Chinese Renmimbi)